APOA1 and coronary artery disorder: On the other hand, in a multi-cohort study, Furtado et al. recently developed a novel enzyme-linked immunosorbent assay (ELISA) that can rapidly and precisely quantify native plasma apoA-I containing lipoprotein (AI-Lp) subspecies [29], based on the functional accessory proteins associated with the particles, and showed that these protein-based subspecies are associated with higher relative risk of coronary heart disease (CHD) [30].